|Type||5 mins||15 mins||Hourly||Daily||Monthly|
|Technical Indicators||Strong Buy||Strong Buy||BUY||Strong Sell||Sell|
|Summary||Strong Buy||Strong Buy||Neutral||Strong Sell||Neutral|
Filter Table By:
|Pattern||Timeframe||Reliability||Candles Ago||Candle Time|
|Three Outside Up||1M||2||Oct 17|
|Bullish Engulfing||1M||3||Sep 17|
|Morning Doji Star||1W||3||Nov 19, 2017|
|Bullish doji Star||1W||4||Nov 12, 2017|
|Homing Pigeon||5H||5||Dec 12, 2017 07:30|
|Oil & Natural Gas||184.80||186.70||184.25||+0.90||+0.49%||1.18M||09:58:46|
|AVT Natural Products Ltd||55.85||57.30||54.80||+1.50||+2.76%||878.60K||09:58:44|
Suven Life Sciences Limited is a bio-pharmaceutical company. The Company is engaged in the business of manufacture and sale of bulk drugs and intermediaries. The Company's segments include Manufacturing (CRAMS), which develops and produces bulk drugs and intermediates under contract manufacturing services; Services (DDDSS), which consists of collaborative research projects (CRP), clinical trials, and testing and analysis services, and Research and Development. Its products consist of active pharmaceutical ingredients (APIs), including Aripiprazole, Armodafinil, Calcium Acetate, Carprofen, Deferasirox, Doxofylline, Entacapone, Fenoprofen Calcium, Rosuvastatin Calcium, Sitagliptin Phosphate and Solifenacin succinate, and intermediates, including 2-nitro phenyl acetic acid and 3,4-dichlorobenzylamine. The Company is engaged in the drug discovery specializing in central nervous system (CNS)-based programs with over four of the molecules in pipeline under clinical phase of development.Read More
Add a Comment
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.